Updates in Treatment Approaches for Prostate Cancer
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: Overview of Metastatic HSPC: Diagnosis and Risk Stratification By Rana R. McKay, MD, University of California San Diego Medical Center, Sumit K. Subudhi, MD, PhD, Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College, Ulka Vaishampayan, MD, Arash Rezazadeh Kalebasty, MD Opening their first module on metastatic hormone-sensitive prostate cancer, panelists consider optimal diagnostic and risk stratification strategies for when a patient presents in clinic.
EP. 2: Systemic Treatment Armamentarium in Metastatic HSPC By Rana R. McKay, MD, University of California San Diego Medical Center, Arash Rezazadeh Kalebasty, MD , Sumit K. Subudhi, MD, PhD, Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College, Ulka Vaishampayan, MD Shared insight on the range of systemic therapy options available to patients who present with metastatic hormone-sensitive prostate cancer.
EP. 3: What is the Role of Locoregional Therapy in Metastatic HSPC? By Rana R. McKay, MD, University of California, San Diego, Arash Rezazadeh Kalebasty, MD , Sumit K. Subudhi, MD, PhD, Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College, Ulka Vaishampayan, MD Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.
EP. 4: Informing Systemic Therapy Selection With Negative Data in HSPC By Rana R. McKay, MD, University of California, San Diego, Arash Rezazadeh Kalebasty, MD , Sumit K. Subudhi, MD, PhD, Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College, Ulka Vaishampayan, MD A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.
EP. 5: Evolving Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer By Rana R. McKay, MD, University of California, San Diego, Arash Rezazadeh Kalebasty, MD , Sumit K. Subudhi, MD, PhD, Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College, Ulka Vaishampayan, MD Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.
EP. 6: Advent of PARP Inhibitors in Metastatic CRPC By Rana R. McKay, MD, University of California, San Diego, Arash Rezazadeh Kalebasty, MD , Sumit K. Subudhi, MD, PhD, Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College, Ulka Vaishampayan, MD Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.
EP. 7: Combination PARPi Strategies in Metastatic CRPC: Interpreting Data From Clinical Trials By Rana R. McKay, MD, University of California, San Diego, Arash Rezazadeh Kalebasty, MD , Sumit K. Subudhi, MD, PhD, Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College, Ulka Vaishampayan, MD Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.
EP. 8: Radioligands in the Treatment of Metastatic CRPC: Lutetium-177–PSMA-617 By Rana R. McKay, MD, University of California, San Diego, Arash Rezazadeh Kalebasty, MD , Sumit K. Subudhi, MD, PhD, Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College, Ulka Vaishampayan, MD Focused discussion on the role of lutetium-177–PSMA-617 as radioligand therapy in patients with metastatic castration-resistant prostate cancer.
EP. 9: Radioligands in the Treatment of Metastatic CRPC: Radium-223 By Rana R. McKay, MD, University of California, San Diego, Arash Rezazadeh Kalebasty, MD , Sumit K. Subudhi, MD, PhD, Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College, Ulka Vaishampayan, MD Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.
EP. 10: Metastatic CRPC: Novel Treatment Strategies With Radioligand Therapy By Rana R. McKay, MD, University of California, San Diego, Arash Rezazadeh Kalebasty, MD , Sumit K. Subudhi, MD, PhD, Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College, Ulka Vaishampayan, MD Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.
EP. 11: Novel Therapeutic Targets in Metastatic CRPC By Rana R. McKay, MD, University of California San Diego Medical Center, Arash Rezazadeh Kalebasty, MD , Sumit K. Subudhi, MD, PhD, Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College, Ulka Vaishampayan, MD A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.
EP. 12: Potential for CDK4/6 Inhibitors in Metastatic CRPC By Rana R. McKay, MD, University of California San Diego Medical Center, Arash Rezazadeh Kalebasty, MD , Sumit K. Subudhi, MD, PhD, Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College, Ulka Vaishampayan, MD Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.
EP. 13: Ongoing Clinical Trials in the Metastatic CRPC Setting By Rana R. McKay, MD, University of California San Diego Medical Center, Arash Rezazadeh Kalebasty, MD , Sumit K. Subudhi, MD, PhD, Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College, Ulka Vaishampayan, MD Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.
EP. 14: CAR T-Cell Therapy in Metastatic CRPC and Future Directions in Care By Rana R. McKay, MD, University of California San Diego Medical Center, Arash Rezazadeh Kalebasty, MD , Sumit K. Subudhi, MD, PhD, Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College, Ulka Vaishampayan, MD Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.
